Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma

Description

This clinical trial constructs and tests a novel multinuclear metabolic magnetic resonance imaging (MRI) sequence in patients with glioma (brain tumor) that is newly diagnosed or has come back (recurrent). This trial aims to develop new diagnostic imaging technology that may bridge gaps between early detection and diagnosis, prognosis, and treatment in brain cancer.

Conditions

Glioma, Malignant Glioma, Recurrent Glioma, Recurrent Malignant Glioma

Talk to us

Study Overview

On this page

Study Details

Study overview

This clinical trial constructs and tests a novel multinuclear metabolic magnetic resonance imaging (MRI) sequence in patients with glioma (brain tumor) that is newly diagnosed or has come back (recurrent). This trial aims to develop new diagnostic imaging technology that may bridge gaps between early detection and diagnosis, prognosis, and treatment in brain cancer.

Simultaneous Multinuclear (Na+/H+) Metabolic MRI in Brain Tumors

Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma

Condition
Glioma
Intervention / Treatment

-

Contacts and Locations

Los Angeles

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States, 90095

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * AIM 1: Healthy volunteers with no evidence of brain tumors or neurologic disease
  • * AIM 1: Age 18+
  • * AIM 2: Newly diagnosed or recurrent suspected or confirmed glioma (low or high grade)
  • * AIM 2: 10 IDH mutant and 10 IDH wild type gliomas
  • * AIM 2: Clinically indicated for resective surgery or biopsy
  • * AIM 2: Age 18+
  • * AIM 2: Tumor size \> 1x1x1 cm (measurable)
  • * AIM 3: Recurrent glioma enrolled in an immunotherapy trial or clinically indicated to receive immunotherapy including anti-PD1
  • * AIM 3: Age 18+
  • * AIM 1: Cannot safely perform an MRI
  • * AIM 1: Age \< 18
  • * AIM 2: Cannot safely perform an MRI or use of MRI contrast agents
  • * AIM 2: Age \< 18
  • * AIM 3: Cannot safely perform an MRI or use of MRI contrast agents
  • * AIM 3: Age \< 18

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Jonsson Comprehensive Cancer Center,

Benjamin M Ellingson, PRINCIPAL_INVESTIGATOR, UCLA / Jonsson Comprehensive Cancer Center

Study Record Dates

2027-09-10